The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).
Bita ShakooryAshley GeerlinksMarta WilejtoKate KernanMelissa HinesMicol RomanoDavid PiskinAngelo RavelliRashmi SinhaDaniel AletahaCarl AllenHamid BassiriEdward M BehrensJoseph CarcilloLinda CarlWinn ChathamJeffrey I CohenRandy Q CronErik DrewniakAlexei A GromLauren A HendersonAnnacarin HorneMichael B JordanKim E NicholsGrant S SchulertSebastiaan VastertErkan DemirkayaRaphaela Goldbach-ManskyFabrizio de BenedettiRebecca A MarshScott W Cannanull nullPublished in: Annals of the rheumatic diseases (2023)
These 2022 EULAR/American College of Rheumatology points to consider provide up-to-date guidance, based on the best available published data and expert opinion. They are meant to help guide the initial evaluation, management and monitoring of patients with HLH/MAS in order to halt disease progression and prevent life-threatening immunopathology.